Pharmaceutical giant Sanofi (SNY 0.78%) and biotech Regeneron (REGN 1.55%) have announced the start of two late-stage clinical trials for their experimental rheumatoid arthritis drug sarilumab. This antibody is being tested in combination with methotrexate, a drug often used for the treatment of rheumatoid arthritis, and will be compared to Amgen (AMGN 1.07%) and Pfizer's (PFE 0.20%) Enbrel. In the following video, health-care analyst Max Macaluso discusses these clinical trials and how this drug could compete in the rheumatoid arthritis market.
Sanofi and Regeneron's Latest Partnership
By Max Macaluso – May 15, 2013 at 9:13PM
NASDAQ: SNY
Sanofi
Market Cap
$121B
Today's Change
(-0.78%) $0.39
Current Price
$49.60
Price as of October 23, 2025 at 3:58 PM ET
Late-stage clinical trials begin for this duo's experimental rheumatoid arthritis drug.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo